## RECEIVED **CENTRAL FAX CENTER**

MAY 1 0 2005



### THE WEBB LAW FIRM

700 Koppers Building 436 Seventh Avenue

Pittsburgh, PA 15219-1818

Telephone: 412-471-8815 Facsimile: 412-471-4094

E-mail: webblaw@webblaw.com

## FACSIMILE INFORMATION SHEET

RESPONSE UNDER 37 C.F.R §1.116 **EXPEDITED PROCEDURE GROUP ART UNIT 1617** 

Name of Individual:

MAIL STOP AF

Commissioner for Patents

Company:

United States Patent and Trademark Office

City and State: Alexandria, VA

Facsimile Number:

703-872-9306

From:

Message:

Kirk M. Miles, Esquire

Total Number of Pages:

Date Transmitted:

May 10, 2005

CV01382K US

Client No.: 4686

Application No. 10/057,629

Inventors: Harry R. Davis

Filed: January 25, 2002

Title: USE OF SUBSTITUTED AZETIDINONE COMPOUNDS FOR THE TREATMENT OF

File No.: 045584

SITOSTEROLEMIA 1005 7629

19957fffansmittal Form (1p)

95/11/2005 AKELECH1 00000052

01 FC:1806

18<del>0:00 DA</del>

Fee Transmittal 1p. (2x)

Supplemental Information Disclosure

Statement (2pp)

Information Disclosure Statement (1p)

Cited Art (9pp)

If you do not receive all pages, please call back as soon as possible. The number is (412) 471-881

#### STATEMENT OF CONFIDENTIALITY

The information in this facsimile is <u>privileged</u> and <u>confidential</u> and is intended only for the use of the named recipient. Disclosure or copying of this document or its contents other than by the named recipient is prohibited. If this document is received in error, it should be returned to sender.

If there are any reception problems, please call 412-471-8815.

MAY-10-2005

Approved for use through 07/31/2006. OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Approved for use through 07/31/2000. Omb uco1-uu31
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paparathic Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB

control number.			prior to desiration of the state of the stat
		Application Number	10/057,629
TRANSMITTAL FORM  (to be used for all correspondence efter initial filing)		Filing Date	January 25, 2002
		First Named Inventor	Harry R. Davis
		Art Unit	1617
		Examiner Name	San Ming R. Hul
Total Number of Pages In This Submission	17	Altorney Docket Number	CV01382K US - 4686-045584

	NCLOSURES (Check all that apply)	······································
	NCLOSURES (Check all that apply)	
☐Fee Transmittal Form	□ Drawing(s)	After Allowance communication     To Technology Center (TC)
■ Fee Attached	☐ Licensing-related Papers	Appeal Communication to Board
☐ Amendment/Reply	☐ Petition	<ul> <li>Appeal Communication to Board of Appeals and Interferences</li> </ul>
☐ After Final	Petition to Convert to a Provisional Application	Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
☐ Affidavits/declaration(s)	☐ Power of Attorney, Revocation	☐ Proprietary Information
☐ Extension of Time Request	Change of Correspondence Address	□ Status Letter
□ Express Abandonment Request	☐ Terminal Disclaimer	
☑ Information Disclosure Statement	☐ Request for Refund	☐ Other Enclosure(s) (please Identify below)
☐ Certified Copy of Priority Documents	CD, Number of CD(s)	
Response to Missing Parts/ Incomplete Application	Remarks	
☐ Response to Missing Parts under 37 CFR 1.52 or 1.53		
	₹r	
SIGNATU	RE OF APPLICANT, ATTORNEY, OR A	GENT
Firm Ann M. Cannoni	VI	
Individual name The Webb Law Firm		
Signature		
Date May 10, 2005		

#### CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facilimite transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mall in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below. Typed or printed name Chris Craig Signature Date 05/10/2005

This collection of Information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will very depending upon the Individual cases. Any comments on the amount of time you require to complete this form anti/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTQ-9199 and select option 2.

MAY-10-2005 15	5:29								Р
· · · · · · · · · · · · · · · · · · ·					U.S.	Patent and Trademan	k Office; U.S. DI	PARTME	OF COM
9 .	Wassing on I	2/08/2004		ed to respond to a	collection of inf	formation unless it dis Complete		B control n	umber.
Fees pursible to the Con				Application	- Number				<del></del>
DEMONSTEE TR			T.	Filing Dat	n Number	10/057,629 January 25, 2	002		
For	r FY	2005			ed Inventor	Harry R. Dav			
Applicant claims	small enrits	status. See 37 C	FR 1.27	Examiner	Name	San Ming R.	Hui		
		· · · · · · · · · · · · · · · · · · ·		Art Unit		1617			
TOTAL AMOUNT O	F PAYMI	ENT (\$) 1	80.00	Attorney	Docket No.	CV01382K U	S/4686-0455	84	
METHOD OF PAYM	ENT (che	k all that apply)							
Check Cre	dit Card	Money Or	der 🔲 N	lone 🔲 O	ther (please is	kartify):			
X Deposit Account	Deposit A	ccount Number.	23-0	650	Deposit Accou	nt Name The W	ebb Law Firn	n	
For the above-ic	ientified depo	sit account, the Dir	ector is hereby	urhorized to: (ch	eck all that am		···		
	fee(s) indica		·	Γ	~	(s) indicated below,	except for the	Ming fee	
X Charge	any addition	al fec(s) or underpa and 1.17	yments of fee(s)	, <u> </u>	<b>≓</b>	overpayments		<b>-</b>	
VARNING: Information of						-	le credit evad		
formation and authorization	m PTO-20	38.			oc 1221244 (	V= 423 1012F 11012	e create care		
FEE CALCULATION	7					•			
. Basic filing, s	EARCH,	AND EXAMIN.	ation fee	\$			·		
	FILI	NG FEES	SEARCE		EXAMINA	ATION FEES			
Application Type	Par (t)	Small Entity		iall Entity		Small Entity			
Unility	<u>Fee (5)</u> 300	<u>Fee.(5)</u> 150	<u>Fee (\$)</u> 500	<u>Fee (\$)</u> 250	Fee (S)	Fee (\$)	Fees	Pald (S)	
	200				200	100			<del></del>
Design Plant		100	100	50	130	65	<del></del>		<del></del>
	200	100	300	150	160	80			
Reignue	300	150	500	<b>25</b> 0	600	300			
Provisional Provisional	200	100	0	<b>O</b> .	0	O	•		
	FEES								Small Enti
								Fee (\$)	Fee (5)
ee Description	Reismes es	ch claim over 20 :	and more than i	a the aniainal m				50 200	25 100
ce Description ach claim over 20 or, for						original natent			
ee Description ach claim over 20 or, for ach independent claim	over 3 or,					original patent			180
ee Description ach claim over 20 or, for ach independent claim	over 3 or, ims				than in the o		ependent Clain	360	180
lee Description lach claim over 20 or, for lach independent claim fultiple dependent claim Total Claims - 20 or	over 3 or, ims <u>Ext</u> HP=	for Reissues, en	Fee (S)	nt claim more	than in the o		ependent Clair Fee Paid (	360 ms	180
ce Description lach claim over 20 or, for lach independent claim fultiple dependent clai  Total Claims	over 3 or, ims <u>Ext</u> HP=	for Reissues, en	Fee (S)	nt claim more	than in the o	Multiple De		360 ms	180
Tee Description Such claim over 20 or, for Such independent claim Aultiple dependent claim Total Chaims - 20 or HP = highest number of the lader, Claims	i over 3 or, ims  Ext HP = oral claims p	for Reissues, en	Fee (S)	nt claim more	than in the o	Multiple De		360 ms	180
Tee Description Such claim over 20 or, for Each independent claim Aultiple dependent claim Total Claims - 20 or HP = highest number of the claims - 3 or Heach Claims - 3 or Heach Claims	ins  Ext  HP =  oral claims p	for Reissues, es	Fee (\$) Fee (\$)	nt claim more	than in the o	Multiple De		360 ms	
Ree Description Such claim over 20 or, for Bach independent claim Multiple dependent claim  - 20 or HP = highest number of to Indep. Claims  - 3 or H P = highest number of independent claims	over 3 or, ims  Ext  HP =  oral claims p  Ext	for Reissues, es	Fee (\$) Fee (\$)	nt claim more	than in the o	Multiple De		360 ms	180
See Description Seeh claim over 20 or, for Each independent claim Multiple dependent claim  - 20 or HP = highest number of the lightest number of independent claims  - 3 or HP = highest number of independent claims	over 3 or, ims  Ext  HP =  oral claims p  Ext  Ext  Ext  Ext  Ext  Ext  Ext  Ex	for Reissues, en	Ecc (S)  an 20  Fee (S)  er than 3	rit claim more  Fee Paid (\$)  Fee Paid (\$)	than in the d	Multiple De Fee (S)	Fee Paid	360 (\$)	
See Description Such claim over 20 or, for Such independent claim Aultiple dependent claim  - 20 or HP = highest number of the highest number of independent claims  - 3 or highest number of independent claims  - 3 or highest number of independent claims  - 3 or highest number of independent claims	over 3 or, ims  Ext  HP =  oral claims p  Ext  Ext  Ext  Ext  Ext  Ext  Ext  Ex	for Reissues, early Claims  X aid for, if greater the ra Claims  X ms paid for, if great	Fee (\$)  Fee (\$)  er than 3	Fee Paid (\$)  Fee Paid (\$)	than in the d	Multiple De  Fee (S)  —————	Fee Paid	360 (\$)	
- 20 or  HP = highest number of the large of	over 3 or, ims  Ext  HP =  oral claims p  Ext  Ext  Ext  Ext  Ext  Ext  Ext  Ex	for Reissues, en	Ecc (S) an 20 Fee (S) er than 3 neets of paper, ereof. See 35	Fee Paid (\$)  Fee Paid (\$)	than in the o	Multiple De Pee (\$) ————————————————————————————————————	Fee Paid	360 (\$)	180 • Paid (\$)

SUBMITTED BY

Signature Registration No. (Attorney/Agent) 35,972 Telephone 412-471-8815

Name (Print/Type) Ann M. Cannoni Date May 10, 2005

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the multiple which is 40 Sile (and by b) 100000 to the control of the cont

180.00


This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is astimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NO SEND FERS OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Committaineer for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Other: Information Disclosure Statement \$180.00

# RECEIVED CENTRAL FAX CENTER

MAY 1 0 2005



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Harry R. Davis et al. : Group Art Unit: 1617

Application No.: 10/057,629 : Examiner: San Ming R. Hui

Filed: January 25, 2002 : Case No.: CV01382K US

For: Use of Substituted Azetidinone : Compounds for the Treatment : Date: May 9, 2005

Of Sitosterolemia

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

	the documer record in the	nts liste above	d on the accompanying Form PTO-1449 be considered and made of p-identified patent application. Copy(ies) of these documents ⊠ are led in related U.S. Application No(s) filed,
,	(b)	No fee	e is believed to be due because:
			This Information Disclosure Statement is being submitted concurrently with the filing of the above-identified application; or
•			This Information Disclosure Statement is being submitted within three (3) months of the filing date of the above-identified application; or
			This Information Disclosure Statement is being submitted concurrently with a Request for Continued Examination (RCE); or
			This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the merits.
	(c)		This Information Disclosure Statement is being submitted before the mailing date of any final action, notice of allowance, or an action that otherwise closes prosecution; and:
05/11/2005 AKELEC	H1 00000052 100	057629	Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
	<del>-</del>		No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this information Disclosure Statement was known to any individual designated in

MAY-10-2005 15:29 P.06

Application No. 10/057,629 Filing Date: January 25, 2002 Paper Dated: May 9, 2005 Page 2

of 2	May 9, 2	2005	
• -			§ 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; or
			The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
(d)	$\boxtimes$	This II	nformation Disclosure Statement is being submitted on or before ayment of the issue fee; and:
			Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
			No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry no item of information contained in this information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filling of this information Disclosure Statement; and
			The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
requir	ed for	this Inf	s hereby authorized to charge any additional fees which may be compared to charge any additional fees which may be compared to 23-0650.
			Respectfully submitted,

By:

Name: Ann Marie Cannoni

Reg. No. 35,972

Dated: May 9, 2005 The Webb Law Firm 436 Seventh Avenue 700 Koppers Building Pittsburgh, PA 15219 Telephone No.: (412) 471-8815 Facsimile No.: (412) 471-4094

 $\boxtimes$ 



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

\* TApplicant(s): Harry R. Davis et al.

Group Art Unit: 1617

Application No.; 10/057,629

Examiner: San Ming R. Hui

Filed:

January 25, 2002

Case No.: CV01382K US

For:

**Use of Substituted Azetidinone** Compounds for the Treatment

Of Sitosterolemia

Date: May 9, 2005

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. § 1.56, it is requested that

**Commissioner for Patents** P.O. Box 1450 Alexandria, VA 22313-1450

(a)

Sir.

record enclos	l in the	above-	on the accompanying Form PTO-1449 be considered and made of dentified patent application. Copy(ies) of these documents   are d in related U.S. Application No(s) filed,
	(b)	No fee	is believed to be due because:
			This Information Disclosure Statement is being submitted concurrently with the filing of the above-identified application; or
			This Information Disclosure Statement is being submitted within three (3) months of the filing date of the above-identified application; or
			This information Disclosure Statement is being submitted concurrently with a Request for Continued Examination (RCE); or
			This Information Disclosure Statement is being submitted prior to the mailing of a first Office Action on the ments.
	(c)		This Information Disclosure Statement is being submitted before the malling date of any final action, notice of allowance, or an action that otherwise closes prosecution; and:
			Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
			No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in

Application No. 10/0 Filing Date: January Paper Dated: May 9 Page 2 of 2	25, 2002	
1 090 2 01 2		§ 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; or
		The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
(d) 🛛		information Disclosure Statement is being submitted on or before ayment of the issue fee; and:
		Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
		No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c), more than three months prior to the filing of this Information Disclosure Statement; and
		The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
	r this inf	s hereby authorized to charge any additional fees which may be formation Disclosure Statement, or credit any overpayment to 23-0650.
		Respectfully submitted,
Dated: May 9, 200 The Webb Law Fin 436 Seventh Aven 700 Koppers Build Pittsburgh, PA 152 Telephone No.: (4 Facsimile No.: (41	m ue ing 19 12) 471-8	By: Name: Ann Marie Cannoni Reg. No. 35,972

**%**-2005

se type a plus sign (+) inside this box → [+]

Approved for use through 10/31/2001. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

der the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for for	m 1449A/PTO			<u> </u>			
				Complete if Known			
INFOR	MATION	DISCLOS	URE	Application Number	10/057,629		
STATE	MENTR	V ADDI IC	ANT	Filing Date	January 25, 2002		
STATEMENT BY APPLICANT (use 15 trainy sheats 25 accessary)				First Named Inventor	Harry R. Davis et al.		
				Group Art Unit	1617		
<b>,</b> —-		•		Examiner Name	San Ming R. Hui		
Sheet	1	of	1	Attorney Docket Number	CV01382KUS/4686-045584		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cite and/or country where published.	T²			
	1	Nguyen LB, et al., "A motecular defect in hepatic cholesterol biosynthesis in sitosterolemia with xanthomatosis" J Clin Invest, 86: 923-931 (1990)				
·						
·						
Finalisas	·	- Inde				

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trudement Office, P.O. Box 1450, Alexandria. VA 22313-1450. DO NOT SEND FRES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

{W0185893.1}

<sup>\*</sup>BXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>2</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>2</sup>For Japaneze patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>3</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.